Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$156.00K$156.00Kderived+21.9% vs Q4 2022 Net Income-$9.34M-$9.34MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$10,332,000N/M Operating Cash Flowderived-$7,139,000N/M Free Cash Flowderived-$7,147,000N/M Margins · derivedOperating margin-6623.1%+714.4 pt vs Q4 2022
Net margin-5985.3%+809.3 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 29, 2024 · 60 d after period end